

Benign Prostatic Hyperplasia (BPH)

REFERENCES

- Anonymous. Histrelin hydrogel implant—valera: histrelin implant, LHRH-hydrogel implant, RL 0903, SPD 424. *Drugs R D*. 2005;6(1):53-5.
- Berges RR, Kassen A, et al. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. *BJU Int*. 2000 May;85(7):842-6.
- Berges RR, Windeler J, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia: Beta-sitosterol Study Group. *Lancet*. 1995 Jun 17;345(8964):1529-32.
- Boehm S, Nirnberger G, et al. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: evidence for its efficacy from studies with mepartricin. *Wien Klin Wochenschr*. 1998 Dec 11;110(23):817-23.
- Boyle P, Robertson C, et al. Updated meta-analysis of clinical trials of *Serenoa repens* extract in the treatment of symptomatic benign prostatic hyperplasia. *BJU Int*. 2004 Apr;93(6):751-6.
- Chen L, Stacewicz-Sapuntzakis M, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. *J Natl Cancer Inst*. 2001 Dec 19;93(24):1872-9.
- Colli E, Rigatti P, et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. *Eur Urol*. 2006 Jan;49(1):82-6.
- Cristoni A, Di PF, et al. Botanical derivatives for the prostate. *Fitoterapia*. 2000 Sep;71(suppl 1):S21-S28.
- Debruyne F, Boyle P, et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients: PERMAL study subset analysis. *Eur Urol*. 2004 Jun;45(6):773-9.
- Debruyne F, Koch G, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. *Eur Urol*. 2002 May;41(5):497-506.
- Djavan B, Nickel JC, et al. The urologist view of BPH progression: results of an international survey. *Eur Urol*. 2002 May;41(5):490-6.
- Dunn CJ, Matheson A, et al. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. *Drugs Aging*. 2002;19(2):135-61.
- Farnsworth WE. Roles of estrogen and SHBG in prostate physiology. *Prostate*. 1996 Jan;28(1):17-23.
- Feustel A, Wennrich R, et al. Zinc, cadmium and selenium concentrations in separated epithelium and stroma from prostatic tissues of different histology. *Urol Res*. 1987;15(3):161-3.
- Gann PH, Hennekens CH, et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. *Prostate*. 1995 Jan;26(1):40-9.
- Gerber GS, Fitzpatrick JM. The role of a lipido-sterolic extract of *Serenoa repens* in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia. *BJU Int*. 2004 Aug;94(3):338-44.
- Giannakopoulos X, Baltogiannis D, et al. The lipidosterolic extract of *Serenoa repens* in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens. *Adv Ther*. 2002 Nov;19(6):285-96.
- Goldmann WH, Sharma AL, et al. Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. *Cell Biol Int*. 2001;25(11):1117-24.

- Gutierrez M, Garcia de Boto MJ, et al. Mechanisms involved in the spasmolytic effect of extracts from *Sabal serrulata* fruit on smooth muscle. *Gen Pharmacol*. 1996 Jan;27(1):171-6.
- Habib FK, Ross M, et al. In vitro evaluation of the pollen extract, cernitin T-60, in the regulation of prostate cell growth. *Br J Urol*. 1990 Oct;66(4):393-7.
- Hryb DJ, Khan MS, et al. The effect of extracts of the roots of the stinging nettle (*Urtica dioica*) on the interaction of SHBG with its receptor on human prostatic membranes. *Planta Med*. 1995 Feb;61(1):31-2.
- Jiang H, Chen Z. [Studies on sex hormone-binding globulin in the prostate]. *Zhonghua Nan Ke Xue*. 2004 Jun;10(6):443-4, 448.
- Kim HS, Bowen P, et al. Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. *Nutr Cancer*. 2003;47(1):40-7.
- Krieg M, Nass R, et al. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. *J Clin Endocrinol Metab*. 1993 Aug;77(2):375-81.
- Kumar SM. Photoselective vaporization of the prostate: a volume reduction analysis in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia and carcinoma of the prostate. *J Urol*. 2005 Feb;173(2):511-3.
- Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. *J Urol*. 2003 Apr;169(4):1520-5.
- Lepor HL, Lowe FC. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Walsh PC, Retik AB, et al, eds. *Campbell's Urology*. Vol 2. 8th ed. Philadelphia, Pa: WB Saunders; 2002:1337-72.
- Lobel B. Screening for prostate cancer--how to manage in 2006? *Acta Chir Iugosl*. 2005;52(4):19-21.
- Lopatkin N, Sivkov A, et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial. *World J Urol*. 2005 Jun;23(2):139-46.
- Occhiato EG, Guarna A, et al. Selective non-steroidal inhibitors of 5 alpha-reductase type 1. *J Steroid Biochem Mol Biol*. 2004 Jan;88(1):1-16.
- Paubert-Braquet M, Cousse H, et al. Effect of the lipidosterolic extract of *Serenoa repens* (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. *Eur Urol*. 1998;33(3):340-7.
- Pham H, Ziboh VA. 5 alpha-reductase-catalyzed conversion of testosterone to dihydrotestosterone is increased in prostatic adenocarcinoma cells: suppression by 15-lipoxygenase metabolites of gamma-linolenic and eicosapentaenoic acids. *J Steroid Biochem Mol Biol*. 2002 Nov;82(4-5):393-400.
- Preuss HG, Marcusen C, et al. Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). *Int Urol Nephrol*. 2001;33(2):217-25.
- Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology, and natural history of BPH. In: Walsh PC, Retik AB, et al, eds. *Campbell's Urology*. Vol 2. 8th ed. Philadelphia, Pa: WB Saunders; 2002:1297-336.
- Safarinejad MR. *Urtica dioica* for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. *J Herb Pharmacother*. 2005;5(4):1-11.
- Scher HI. Hyperplastic and malignant diseases of the prostate. In: Braunwald E, Fauci AS, et al, eds. *Harrison's Principles of Internal Medicine*. 15th ed. New York, NY: McGraw-Hill; 2001:608-16.
- Schulman C. Impact of treatment of BPH on sexuality. *Prostate Cancer Prostatic Dis*. 2001;4(S1):S12-6.
- Sciarra F, Toscano V. Role of estrogens in human benign prostatic hyperplasia. *Arch Androl*. 2000 May-Jun;44(3):213-20.
- Shibata Y, Ito K, et al. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. *Prostate*. 2000

Jan;42(1):45-55.

Sugimura Y. Clinics in prostate cancer [in Japanese]. *Rinsho Byori*. 2004 Jul;52(7):604-10.

Suzuki K, Okazaki H, et al. Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy. *Prostate*. 1998 Oct 1;37(2):70-6.

Tahmatzopoulos A, Kyprianou N. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? *Prostate*. 2004 Apr 1;59(1):91-100.

Tarlatzis BC, Bili HN. Gonadotropin-releasing hormone antagonists: impact of IVF practice and potential non-assisted reproductive technology applications. *Curr Opin Obstet Gynecol*. 2003 Jun;15(3):259-64.

Thomas JA. Diet, micronutrients, and the prostate gland. *Nutr Rev*. 1999 May;57(4):95-103.

Wilt T, Ishani A, et al. *Pygeum africanum* for benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2002b;1:CD001044.

Wilt T, Ishani A, et al. *Serenoa repens* for benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2002a;3:CD001423.

Yasumoto R, Kawanishi H, et al. Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia. *Clin Ther*. 1995 Jan-Feb;17(1):82-7.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

LifeExtension[®]

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.